Foundayo Product Range
Pricing shown after login
-
Foundayo Tablets 5.5mg (30) (POM) ▼
Login to buyFoundayo▼ (orforglipron) film-coated tablets
Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.
Licensed indications:
- Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity
Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.
Report adverse reactions via the MHRA Yellow Card scheme.
-
Foundayo Tablets 9mg (30) (POM) ▼
Login to buyFoundayo▼ (orforglipron) film-coated tablets
Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.
Licensed indications:
- Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity
Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.
Report adverse reactions via the MHRA Yellow Card scheme.
-
Foundayo Tablets 2.5mg (30) (POM) ▼
Login to buyFoundayo▼ (orforglipron) film-coated tablets
Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.
Licensed indications:
- Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity
Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.
Report adverse reactions via the MHRA Yellow Card scheme.
-
Foundayo Tablets 17.2mg (30) (POM) ▼
Login to buyFoundayo▼ (orforglipron) film-coated tablets
Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.
Licensed indications:
- Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity
Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.
Report adverse reactions via the MHRA Yellow Card scheme.
-
Foundayo Tablets 14.5mg (30) (POM) ▼
Login to buyFoundayo▼ (orforglipron) film-coated tablets
Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.
Licensed indications:
- Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity
Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.
Report adverse reactions via the MHRA Yellow Card scheme.
-
Foundayo Tablets 0.8mg (30) (POM) ▼
Login to buyFoundayo▼ (orforglipron) film-coated tablets
Pharmacology: Oral small-molecule (non-peptide) GLP-1 receptor agonist.
Licensed indications:
- Weight management in adults, as an adjunct to a reduced-calorie diet and increased physical activity, with initial BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity
Administration: Oral, once daily at any time, with no food or water restrictions. Swallow whole. Missed dose: take as soon as possible, never more than one tablet a day. No adjustment for age, renal impairment or mild-to-moderate hepatic impairment. Not recommended in severe hepatic impairment or under 18s.
Report adverse reactions via the MHRA Yellow Card scheme.
Frequently asked questions
Clinical and supply questions, answered for practitioners.
What is required to order Foundayo?
Who can open a prescriber account?
Where do I find prescribing information?
What dose strengths are available?
How is Foundayo stored and shipped?
Can this page be shared with patients?
Buy Foundayo Online with Healthxchange
New accounts approved in under 2 hours* including Marketing Portal access.
Order the full range in e-Pharmacy, book Academy training, or speak to your Business Development Manager.